Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters











Database
Language
Publication year range
1.
Diabetes ; 50(10): 2296-300, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11574411

ABSTRACT

Thiazolidinediones, insulin-sensitizing agents, have been reported to increase glucose uptake along with the expression of glucose transporters in adipocytes and cardiomyocytes. Recently, we have further suggested that the translocation of GLUT4 is stimulated by thiazolidinediones in L6 myocytes. However, the direct effects of thiazolidinediones on translocation of glucose transporters have not yet been determined. In this study, using hemagglutinin epitope-tagged GLUT4 (GLUT4-HA), we provide direct evidence of the effect of troglitazone on the translocation of GLUT4 in rat epididymal adipocytes. Primary cultures of rat adipocytes were transiently transfected with GLUT4-HA and overexpressed eightfold compared with endogenous GLUT4 in transfected cells. A total of 24 h of treatment with troglitazone (10(-4) mol/l) increased the cell surface level of GLUT4-HA by 1.5 +/- 0.03-fold (P < 0.01) without changing the total amount of GLUT4-HA, whereas it increased the protein level of endogenous GLUT4 (1.4-fold) without changing that of GLUT1. Thus, the direct effect on the translocation can be detected apart from the increase in endogenous GLUT4 content using GLUT4-HA. Troglitazone not only increased the translocation of GLUT4-HA on the cell surface in the basal state but also caused a leftward shift in the dose-response relations between GLUT4-HA translocation and insulin concentration in the medium (ED(50): from approximately 0.1 to 0.03 nmol/l). These effects may partly contribute to the antidiabetic activity of troglitazone in patients with obesity and type 2 diabetes.


Subject(s)
Adipocytes/metabolism , Chromans/pharmacology , Monosaccharide Transport Proteins/metabolism , Muscle Proteins , Thiazoles/pharmacology , Thiazolidinediones , Animals , Biological Transport/drug effects , Epitopes , Glucose Transporter Type 1 , Glucose Transporter Type 4 , Hemagglutinins/immunology , Hemagglutinins/metabolism , Insulin/pharmacology , Male , Rats , Rats, Sprague-Dawley , Troglitazone
2.
Endocrinology ; 142(10): 4189-94, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11564673

ABSTRACT

Uncoupling protein 3 (UCP3), which uncouples electron transport from ATP synthesis, is expressed at high levels in the skeletal muscle, an important organ in glucose and lipid metabolism. Because several reports proposed that fatty acids induced UCP3 gene expression in skeletal muscle in vivo, in the present study we examined the regulation of UCP3 gene expression by various fatty acids using L6 myotubes. UCP3 gene expression was increased in L6 myotubes by various fatty acids or by alpha-bromopalmitate, a nonmetabolized derivative of palmitic acid. Because fatty acids are also known as agonists for PPARs, we examined the involvement of PPARs in the regulation of the UCP3 gene expression. L-165041, a PPAR delta agonist, increased UCP3 gene expression in L6 myotubes, whereas neither Wy 14,643, a PPAR alpha agonist, nor Pioglitazone, a PPAR gamma agonist, increased it. Therefore, we conclude that UCP3 gene expression is increased by the activation of PPAR delta in L6 myotubes and postulate that PPAR delta mediates at least some part of the increased UCP3 gene expression by fatty acids in skeletal muscle in vivo.


Subject(s)
Carrier Proteins/genetics , Muscle, Skeletal/physiology , Receptors, Cytoplasmic and Nuclear/physiology , Transcription Factors/physiology , Animals , Cell Line , Fatty Acids/pharmacology , Ion Channels , Mitochondrial Proteins , Rats , Receptors, Cytoplasmic and Nuclear/agonists , Signal Transduction/drug effects , Transcription Factors/agonists , Uncoupling Protein 3 , Up-Regulation/drug effects
3.
Diabetes ; 50(5): 1093-101, 2001 May.
Article in English | MEDLINE | ID: mdl-11334413

ABSTRACT

A number of studies have demonstrated that insulin resistance in the skeletal muscle plays a pivotal role in the insulin resistance associated with obesity and type 2 diabetes. A decrease in GLUT4 translocation from the intracellular pool to the plasma membranes in skeletal muscles has been implicated as a possible cause of insulin resistance. Herein, we examined the effects of an insulin-sensitizing drug, troglitazone (TGZ), on glucose uptake and the translocation of GLUT4 in L6 myotubes. The prolonged exposure (24 h) of L6 myotubes to TGZ (10(-5) mol/l) caused a substantial increase in the 2-deoxy-[3H]D-glucose (2-DG) uptake without changing the total amount of the glucose transporters GLUT4, GLUT1, and GLUT3. The TGZ-induced 2-DG uptake was completely abolished by cytochalasin-B (10 micromol/l). The ability of TGZ to translocate GLUT4 from light microsomes to the crude plasma membranes was greater than that of insulin. Both cycloheximide treatment (3.5 x 10(-6) mol/l) and the removal of TGZ by washing reversed the 2-DG uptake to the basal level. Moreover, insulin did not enhance the TGZ-induced 2-DG uptake additively. The TGZ-induced 2-DG uptake was only partially reversed by wortmannin to 80%, and TGZ did not change the expression and the phosphorylation of protein kinase B; the expression of protein kinase C (PKC)-lambda, PKC-beta2, and PKC-zeta; or 5'AMP-activated protein kinase activity. a-Tocopherol, which has a molecular structure similar to that of TGZ, did not increase 2-DG uptake. We conclude that the glucose transport in L6 myotubes exposed to TGZ for 24 h is the result of an increased translocation of GLUT4. The present results imply that the effects of troglitazone on GLUT4 translocation may include a new mechanism for improving glucose transport in skeletal muscle.


Subject(s)
Chromans/pharmacology , Monosaccharide Transport Proteins/genetics , Monosaccharide Transport Proteins/metabolism , Muscle Proteins , Muscle, Skeletal/metabolism , Nerve Tissue Proteins , Thiazoles/pharmacology , Thiazolidinediones , Animals , Biological Transport/drug effects , Cell Line , Cell Membrane/metabolism , Cycloheximide/pharmacology , Deoxyglucose/metabolism , Gene Expression Regulation/drug effects , Glucose Transporter Type 1 , Glucose Transporter Type 3 , Glucose Transporter Type 4 , Insulin/pharmacology , Kinetics , Muscle, Skeletal/cytology , Muscle, Skeletal/drug effects , Protein Transport/drug effects , RNA, Messenger/genetics , Rats , Receptors, Cytoplasmic and Nuclear/genetics , Rosiglitazone , Transcription Factors/genetics , Transcription, Genetic/drug effects , Troglitazone
4.
Metabolism ; 49(3): 326-30, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10726909

ABSTRACT

Free fatty acid (FFA) has been reported to decrease leptin mRNA levels in 3T3-L1 adipocytes. When using this cell line, it is difficult to determine the protein levels because a very small amount of leptin is secreted into the medium. The effect of FFA on leptin secretion from adipocytes has not yet been determined. In addition, in vivo studies have failed to demonstrate a FFA-induced decrease in plasma leptin levels. To clarify the effect of FFA on leptin production, we investigated the leptin protein level in the medium and the mRNA level in primary cultured rat adipocytes treated with triacsin C, which is a potent inhibitor of acyl-coenzyme A (CoA) synthetase, palmitate, and 2-bromopalmitate. Triacsin C (0 to 5 x 10(-5) mol/L) decreased leptin concentrations in the culture medium in a dose-dependent manner. Leptin mRNA levels were decreased to 10% of the control in the presence of triacsin C. The concentration of triacsin C needed to suppress leptin production was similar to the Ki value (approximately 10(-5) mol/L) for inhibition of acyl-CoA synthetase. Both palmitate and 2-bromopalmitate decreased leptin concentra-tions but did not affect the triacsin C-induced decrease in leptin additively. In conclusion, both protein and mRNA levels of leptin were decreased by triacsin C and FFA in primary cultured rat adipocytes. Our findings suggest that FFA is involved in the regulation of leptin production in adipocytes.


Subject(s)
Adipocytes/metabolism , Gene Expression Regulation/drug effects , Hypoglycemic Agents/pharmacology , Leptin/genetics , Palmitates/pharmacology , Palmitic Acid/pharmacology , Triazenes/pharmacology , Adipocytes/drug effects , Animals , Cells, Cultured , Coenzyme A Ligases/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Epididymis , Kinetics , Male , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Transcription, Genetic/drug effects
5.
Metabolism ; 48(12): 1570-4, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10599990

ABSTRACT

Leptin, which is secreted from adipocytes, has a role in the regulation of appetite and energy expenditure. The thyrotropin receptor (TSH-R) was recently found in adipocytes. We examined the effects of TSH on leptin production and lipolysis in rat epididymal adipocytes. TSH decreased the concentration of leptin in the medium time (approximately 24 hours)- and dose (approximately 10(-7) mol/L)-dependently (half-maximal inhibition [IC50] approximately 10(-9) mol/L). TSH also decreased the ob mRNA level approximately 55% in adipocytes. We confirmed the presence of TSH-R mRNA in the adipocytes by reverse transcription-polymerase chain reaction (RT-PCR). TSH stimulated glycerol release dose-dependently (IC50 approximately 10(-8) mol/L) in adipocytes. This TSH-induced glycerol release was further enhanced by adenosine deaminase (ADA). In summary, TSH reduced leptin production and stimulated lipolysis in rat epididymal adipocytes. Although the pathophysiological relevance of the regulation of leptin production and lipolysis by TSH is unknown, we speculate that TSH may affect the regulation of appetite and energy expenditure in pathophysiological states.


Subject(s)
Adipocytes/metabolism , Leptin/biosynthesis , Thyrotropin/pharmacology , Animals , Leptin/genetics , Lipolysis/drug effects , Lipoprotein Lipase/genetics , Male , Osmolar Concentration , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Thyrotropin/genetics
6.
Intern Med ; 35(8): 646-9, 1996 Aug.
Article in English | MEDLINE | ID: mdl-8894740

ABSTRACT

A 59-year-old man visited Kyoto University Hospital because of general malaise, polyuria, and polydipsia. The diagnosis of primary hyperparathyroidism was made based on hypercalcemia and an elevated circulating PTH level. A nodule was palpable in the left anterior neck. Two weeks later, the serum calcium level was normalized and his symptoms subsided. A temporary expansion, followed by reduction of the tumor size was observed by serial ultrasonography. Histology of the resected tumor showed central necrotic tissue, with some peripherally remaining glandular tissue. We report here a rare case of primary hyperparathyroidism with spontaneous remission due to hemorrhagic infarction in the adenoma.


Subject(s)
Adenoma/complications , Hemorrhage/complications , Hyperparathyroidism/complications , Infarction/complications , Parathyroid Neoplasms/complications , Adenoma/diagnostic imaging , Adenoma/pathology , Alkaline Phosphatase/blood , Calcium/blood , Humans , Hyperparathyroidism/blood , Magnetic Resonance Imaging , Male , Middle Aged , Parathyroid Hormone/blood , Parathyroid Neoplasms/diagnostic imaging , Parathyroid Neoplasms/pathology , Remission, Spontaneous , Time Factors , Ultrasonography
SELECTION OF CITATIONS
SEARCH DETAIL